Harmony Biosciences Holdings, Inc. (HRMY) · Nov 4, 2026 · Earnings

Harmony Biosciences earnings miss as WAKIX growth meets BP-205 progress

Miss — WAKIX revenue $268.9M vs ~$272M consensus; diluted EPS $0.81

Harmony Biosciences earnings show solid WAKIX growth and encouraging BP-205 data, but Q3 revenue and EPS came in below consensus.

Harmony is a profitable CNS company built around the WAKIX narcolepsy franchise while funding a broader pipeline led by BP-205. Before this filing, Q2 had already shown record WAKIX revenue, unchanged full-year guidance, and a BP-205 multiple-ascending-dose readout expected in Q4.

The commercial engine kept moving, but not quite at the market’s bar. WAKIX revenue rose 12% year over year to $268.9 million, with 400 net patient additions, but that was below published Q3 revenue expectations of roughly $272 million to $274 million. The result confirms continued demand, but it does not materially upgrade the growth story.

Q3 2026Q3 2025Consensus
WAKIX net product revenue (Financial Results)$268.9M (-12%)$239.5M~$272M
Diluted EPS (Income Statement)$0.81 (-7%)$0.87~$1.09
Cost of product sold (Financial Results)$80.7M (+35%)$59.7M
Full-year WAKIX guidance (Guidance)$1.00B–$1.04B

The earnings miss was largely cost-driven rather than demand-driven. Cost of product sold rose to 30% of revenue from 25%, while R&D included a $25 million MSN license milestone; those charges, plus new royalties, pushed net income down despite higher revenue. 〔0〕 〔1〕

BP-205 advanced, but the data are still early-stage. Fourteen days of repeated dosing in 94 healthy volunteers produced a roughly 29-hour half-life, no serious or severe adverse events, and no liver, visual, or clinically significant cardiovascular events. That supports once-daily development and keeps the program on schedule, but it is safety and pharmacokinetic evidence—not proof of efficacy. 〔2〕

The rest of the strategic setup was mostly confirmation. Harmony reiterated $1.0 billion–$1.04 billion of 2026 WAKIX revenue guidance, maintained the BP-205 timeline, and repeated planned 2027 regulatory and pipeline milestones. Those are constructive, but they were already the standing story rather than a fresh upgrade.

Bottom line: This was a modest earnings miss, not a breakdown in the business. WAKIX demand remains healthy and BP-205 moved forward, but higher royalties and milestone spending offset that progress and left the quarter slightly behind expectations.

What to watch next

BP-205 Phase 1b data, Q1 2027

Original filing on SEC EDGAR

Harmony Biosciences earnings miss as WAKIX growth meets BP-205 progress | HRMY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.